arrow
F

Filip Eftimov

amsterdamumc
H指数:36
被引数:5,422

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy

第十二届关于IgM及华氏巨球蛋白血症相关神经病变患者管理国际研讨会共识专家组1的报告

2025-05-020
PRE
Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment

在免疫抑制治疗下,经多次mRNA疫苗接种后SARS-CoV-2抗体谱的演变

2025-03-010
PRE
Deep profiling of B cells responding to various pathogens uncovers compartments in IgG memory B cell and antibody-secreting lineages

对响应各种病原体的B细胞进行深度分析,揭示了IgG记忆B细胞和抗体分泌谱系中的隔室。

2025-02-211
OA
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy

COVID-19疾病和疫苗接种对特应性皮炎、银屑病和白癜风等皮肤免疫介导性炎症疾病的影响:一项Target2B!子研究

2025-02-141
OAAI
Longevity of antibody responses is associated with distinct antigen-specific B cell subsets early after infection
2024-12-170
OAAI
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
2024-05-102
OAAI
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
2024-04-011
OA
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

T细胞活化标志物CD38和hla-dr指示SARS-CoV-2 mRNA疫苗接种后anti-CD20-treated多发性硬化症患者的非血清转化

2024-03-281
OAAI
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination

mRNA疫苗接种后,dupilumab和TNF抑制剂治疗的患者抑制了IgG4类别转换

2024-03-046
OAAI
Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

SARS-CoV-2疫苗接种或感染后类风湿因子自身抗体的纵向反应

2024-02-290
OAAI